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Relationship of High-Density Lipoprotein Cholesterol With Renal
Function in Patients Treated With Atorvastatin
Kwok Leung Ong, PhD; David D. Waters, MD; Rana Fayyad, PhD; Liffert Vogt, MD, PhD; Shari Melamed, MD; David A. DeMicco, DPharm;
Kerry-Anne Rye, PhD; Philip J. Barter, MD, PhD
Background-—It is not known whether the concentration of high-density lipoprotein (HDL) cholesterol is related to renal function in
statin-treated patients. We therefore investigated whether HDL cholesterol levels predicted renal function in atorvastatin-treated
patients in the TNT (Treating to New Targets) trial.
Methods and Results-—A total of 9542 participants were included in this analysis. Renal function was assessed by estimated
glomerular ﬁltration rate (eGFR). HDL cholesterol levels at month 3 were used as this is the time point at which on-treatment HDL
cholesterol levels became stable. Among 6319 participants with a normal eGFR (≥60 mL/min per 1.73 m2) at baseline, higher HDL
cholesterol levels at month 3 were signiﬁcantly associated with lower risk of decline in eGFR (ie, having eGFR <60 mL/min per
1.73 m2) during follow-up (HR of 1.04, 0.88, 0.85, and 0.77 for HDL cholesterol quintiles 2, 3, 4, and 5, respectively, relative to
quintile 1, P for trend=0.006). Among 3223 participants with an eGFR (<60 mL/min per 1.73 m2) at baseline, higher HDL
cholesterol levels at month 3 had less impact on eGFR during follow-up, with statistical signiﬁcance observed only when analyzing
HDL cholesterol levels as a continuous variable (P=0.043), but not as a categorical quintile variable (P for trend=0.27).
Conclusions-—In patients treated with atorvastatin, higher HDL cholesterol levels were associated with lower risk of eGFR decline
in patients with normal eGFR at baseline. However, further study is needed to establish whether there is any causal relationship
between HDLs and renal function.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00327691. ( J Am Heart Assoc. 2018;7:
e007387. DOI: 10.1161/JAHA.117.007387.)
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E pidemiological studies have suggested that people withelevated plasma high-density lipoprotein (HDL) choles-
terol levels are at decreased cardiovascular risk.1 Patients
with chronic kidney disease (CKD) often have abnormalities of
plasma lipids and lipoproteins, including a reduced level of
HDL cholesterol.2 Previous longitudinal studies investigating
the relationship of low levels of HDL cholesterol (or its main
apolipoprotein, apoA-I) on kidney function have been incon-
sistent, with both positive3–5 and negative ﬁndings
reported.6,7 It is not known whether a low HDL cholesterol
level can predict either CKD or a decline in renal function in
patients who are treated with a statin. Recent ﬁndings from
the PLANET I (Prospective Evaluation of Proteinuria and Renal
Function in Diabetic Patients With Progressive Renal Disease)
and PLANET II (Prospective Evaluation of Proteinuria and Renal
Function in Non-diabetic Patients With Progressive Renal
Disease) studies have demonstrated that atorvastatin ren-
dered better renoprotection as compared with rosuvastatin.8
Moreover, these studies showed that patients randomized to
atorvastatin had stabilization of eGFR during follow-up, while
those randomized to rosuvastatin still had progression of
eGFR decline. Post hoc analyses of other double-blind
placebo-controlled randomized controlled trials indicate that
treatment with atorvastatin is associated with eGFR improve-
ment over time.9–11 The mechanism explaining the discrepant
effects within the same class of statins on eGFR trajectories is
unclear. In this study, we investigated whether HDL cholesterol
levels predict renal function in the Treating to New Targets (TNT)
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trial, a double-blind controlled trial in which patients with stable
coronary disease were randomized to 2 doses of atorvastatin
(either 10 or 80 mg daily).12
Methods
Study Population
The study design and results of the TNT trial have been
published.12 Brieﬂy, 10 001 patients with stable coronary
disease and a low-density lipoprotein (LDL) cholesterol level
off-therapy of 3.4 to 6.5 mmol/L (130–250 mg/dL), decreas-
ing to <3.4 mmol/L (130 mg/dL) after an 8-week run-in
period on atorvastatin 10 mg/d, were randomized to 10 mg or
80 mg/d of atorvastatin. Mean LDL cholesterol during follow-
up was 2.6 mmol/L (101 mg/dL) in the 10 mg/d group and
2.0 mmol/L (77 mg/dL) in the 80 mg/d group. All patients
gave written informed consent. The study was approved by
local research ethics committees or institutional review boards
at each center, and was performed in accordance with the
Helsinki Declaration. Pﬁzer’s policies on the provision of
clinical trial data are set out on their website (http://www.pf
izer.com/research/clinical_trials/trial_data_and_results). In
addition to posting clinical trial results on the clinicaltrials.gov
registry, Pﬁzer will provide access to anonymized patient-level
data in response to scientiﬁcally valid research protocols.
Renal Function
Renal function was assessed using the estimated glomerular
ﬁltration rate (eGFR), calculated using the creatinine-based
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation.13 Serum creatinine measurements using the mod-
iﬁed alkaline picrate method of Jaffe14,15 were taken at
baseline and after 12, 24, 36, 48, 60, and 72 months of
treatment by individuals. The assays were conducted at a
central study laboratory that was blinded to treatment
assignment. Details on creatinine measurements and quality
control assurance have been described previously.9 Baseline
was deﬁned as the time of randomization, when all patients
had been taking atorvastatin 10 mg/d for at least 8 weeks.
Statistical Analysis
For this study, subjects were stratiﬁed into quintiles based on
their HDL cholesterol levels determined at the 3-month time
point of the double-blind treatment phase. HDL cholesterol
levels at month 3 were used as this is the time point at
which HDL cholesterol levels became stable after statin
treatment.12,16 Data were presented as meanSD or
percentage (n).
As data on serum creatinine were collected at baseline and
after 12, 24, 36, 48, 60, and 72 months of treatment by
individuals, eGFR was calculated for each individual at all
available visits. The association of quintile of HDL cholesterol
level at month 3 with time-to-ﬁrst decline or improvement in
eGFR was assessed by the Cox proportional hazard regression
analysis, and hazard ratios were estimated with and without
adjustment for important covariates. Participants with a
normal eGFR (≥60 mL/min per 1.73 m2) at baseline were
deﬁned to have a decline in eGFR if their eGFR levels were
<60 mL/min per 1.73 m2 during follow-up. Participants with
an abnormal eGFR (<60 mL/min per 1.73 m2) at baseline
were deﬁned to have improvement in eGFR if their eGFR levels
increased to ≥60 mL/min per 1.73 m2 during follow-up. In
this analysis, for each participant who developed events
(decline or improvement in eGFR), the time to event (number
of days) was considered as the time interval between the date
of the visit at which the earliest event was ascertained and
the date of randomization. For participants who remained
event-free, the follow-up time was censored at last visit or last
day known to be alive, whichever was later. For subjects who
died, the follow-up time was censored at their death date. The
proportional hazards assumption was checked using Schoen-
feld residuals and by adding an interaction between HDL
cholesterol at month 3 and event time as a time-dependent
covariate. No signiﬁcant violation of proportional hazards
assumption was found for both decline and improvement in
eGFR. The covariates considered in the Cox regression
analyses were prespeciﬁed variables that may affect HDL
cholesterol, other lipids, and risk factors for CKD and CVD.
These included treatment allocation, age, sex, smoking status,
body mass index, systolic blood pressure, fasting glucose,
LDL cholesterol, triglyceride levels, ratio of apoB to apoA-I,
Clinical Perspective
What Is New?
• In patients treated with atorvastatin from the TNT (Treating
to New Targets) trial, higher high-density lipoprotein (HDL)
cholesterol levels were associated with lower risk of
estimated glomerular ﬁltration rate decline in patients with
normal estimated glomerular ﬁltration rate at baseline.
• However, higher HDL cholesterol levels were not robustly
associated with an improvement in estimated glomerular
ﬁltration rate during follow-up.
What Are the Clinical Implications?
• This study provides evidence that higher HDL cholesterol
levels may predict a lower risk of renal function decline in
patients with normal renal function at baseline, even on
treatment with a statin.
• In patients with renal impairment, increasing HDL choles-
terol level may not improve renal function.
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and the presence or absence of a history of diabetes mellitus,
myocardial infarction, cerebrovascular accident, and hyper-
tension at baseline, as well as LDL cholesterol and
triglycerides at month 3 of the trial.16 In a separate analysis,
HDL cholesterol levels at month 3 were analyzed as a
continuous variable, rather than as a categorical quintile
variable. A 2-sided P<0.05 was considered statistically
signiﬁcant.
Results
Figure shows the ﬂow diagram of the study participants. Of
the overall TNT population, 9656 participants (4829 on
10 mg/d atorvastatin and 4827 on 80 mg/d atorvastatin)
had complete renal data (both baseline and postbaseline
eGFR). After excluding 114 patients with missing data on HDL
cholesterol levels at month 3, 9542 participants were
included in this analysis. Table 1 shows the baseline charac-
teristics of these 9542 participants included in this analysis
and 459 participants excluded from the analysis. There was
no signiﬁcant difference in age, body mass index, blood
pressure, atorvastatin treatment allocation and HDL choles-
terol at baseline, as well as HDL cholesterol at month 3
between these 2 groups, although participants excluded from
this study were less likely to be men with white race, and
were more likely to have higher total cholesterol, LDL
cholesterol, and triglyceride levels at baseline (Table 1).
Table 2 shows the baseline characteristics of the patients
according to HDL cholesterol level at month 3. Participants
who had higher HDL cholesterol at month 3 were more likely
to be female and not a current smoker, with lower body mass
index, lower fasting glucose, lower plasma triglyceride levels,
but higher age, higher systolic blood pressure, higher total
cholesterol levels, and higher HDL cholesterol levels at
baseline. They were also less likely to be in the high-dose
atorvastatin group, and less likely to have a history of
diabetes mellitus, myocardial infarction, coronary artery
bypass graft, cerebrovascular accident, peripheral vascular
disease, and congestive heart failure. The median follow-up
duration was 4.9 (interquartile range: 4.6–5.2) years, which
was the same for each quintile.
As shown in Table 3, the proportion of participants with
normal eGFR (≥60 mL/min per 1.73 m2) at baseline was
lower in those with higher HDL cholesterol levels at month
3 (63.3% in those in the highest quintile of HDL cholesterol
versus 68.0% in those in the lowest HDL cholesterol
quintile, P=0.002). However, within each quintile of HDL
cholesterol level at month 3, eGFR increased signiﬁcantly,
and to approximately the same extent in all HDL
cholesterol quintiles, from baseline to the last visit (all
P<0.001).
As shown in Table 4, among 6319 participants with a
normal eGFR (≥60 mL/min per 1.73 m2) at baseline, higher
HDL cholesterol levels at month 3 were signiﬁcantly associ-
ated with a lower risk of a decline in eGFR (ie, having eGFR
<60 mL/min per 1.73 m2) during follow-up after adjusting for
age, sex, and treatment allocation. The association remained
signiﬁcant in the full adjustment model. Among 3223
Figure. Flow diagram of study participants. HDL indicates high-
density lipoprotein; TNT, Treating to New Targets.
Table 1. Baseline Characteristics Between Participants
Included and Not Included in This Study
Baseline
Characteristics
Included in
This Study
Excluded in
This Study P Value
n 9542 459
Age, y 61.08.8 60.9 (9.3) 0.76
Male sex 7746 (81.2%) 353 (76.9%) 0.023
White race 8990 (94.2%) 420 (91.5%) 0.016
Body mass
index, kg/m2
28.54.5 28.55.1 0.96
Systolic blood
pressure, mm Hg
130.716.7 131.117.3 0.64
Diastolic blood
pressure, mm Hg
77.99.5 78.49.3 0.32
Treatment with
atorvastatin 80 mg
4763 (49.9%) 232 (50.5%) 0.79
Baseline lipids, mg/dL
Total cholesterol 174.623.7 177.726.6 0.0066
LDL cholesterol 97.417.5 99.419.6 0.017
HDL cholesterol 47.310.9 46.911.5 0.41
Triglycerides 150.270.5 158.878.2 0.012
HDL cholesterol
at mo 3, mg/dL
47.311.2 47.011.8 0.75
Data are expressed as meanSD or n (%). Comparison of baseline characteristics at
randomization were performed using a v2 test for categorical variables, and ANOVA for
continuous variables. HDL indicates high-density lipoprotein; LDL, low-density
lipoprotein.
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participants with lower eGFR (<60 mL/min per 1.73 m2) at
baseline, higher HDL cholesterol levels at month 3 were not
robustly associated with an improvement in eGFR (ie, having
eGFR ≥60 mL/min per 1.73 m2) during follow-up in the full
adjustment model, with statistical signiﬁcance only when
analyzing HDL cholesterol levels as a continuous variable, but
not as a categorical variable. In a separate analysis, similar
results were obtained when sex-speciﬁc cutoff points were
used to deﬁne quintiles, instead of the categorical quintile
variable (data not shown).
Discussion
This is the ﬁrst report of the association of HDL cholesterol levels
with change in renal function in patients treated with a statin in a
large-scale double-blind clinical trial. In this analysis of atorvas-
tatin-treated patients, we observed a signiﬁcant association of
higher HDL cholesterol levels with a lower risk of eGFR decline in
patients in whom eGFR was normal at baseline. However, higher
HDL cholesterol levels were not associated with improvement in
eGFR in patients with lower baseline levels of eGFR.
Table 2. Baseline Characteristics of the Participants According to Quintile of HDL Cholesterol at Month 3
Baseline Characteristics
HDL Cholesterol at 3 Mo
P for TrendQuintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
n 2033 1977 1828 1819 1885 
HDL cholesterol range, mg/dL 19 to 38 39 to 43 44 to 48 49 to 55 56 to 116 
Treatment with atorvastatin 80 mg 1043 (51.3%) 1030 (52.1%) 901 (49.3%) 874 (48.0%) 915 (48.5%) 0.008
Age, y 59.19.2 60.38.8 61.38.6 61.88.7 62.98.3 <0.001
Male sex 1866 (91.8%) 1744 (88.2%) 1504 (82.3%) 1427 (78.4%) 1205 (63.9%) <0.001
White race 1909 (93.9%) 1857 (93.9%) 1723 (94.3%) 1720 (94.6%) 1781 (94.5%) 0.29
Body mass index, kg/m2 29.84.7 29.04.7 28.64.3 28.04.2 27.24.3 <0.001
Smoking status
Current 402 (19.8%) 293 (14.8%) 188 (10.3%) 200 (11.0%) 171 (9.1%) <0.001
Former 1249 (61.4%) 1259 (63.7%) 1180 (64.6%) 1154 (63.4%) 1206 (64.0%)
Never 382 (18.8%) 425 (21.5%) 460 (25.2%) 465 (25.6%) 508 (26.9%)
Systolic blood pressure, mm Hg 129.517.3 129.916.0 131.116.7 130.716.7 132.416.8 <0.001
Diastolic blood pressure, mm Hg 77.89.6 77.99.5 78.29.2 77.69.4 78.29.5 0.51
Fasting glucose, mg/dL 113.435.2 109.731.8 106.628.2 105.228.1 102.826.8 <0.001
Lipids, mg/dL
Total cholesterol 169.324.0 170.823.3 173.523.0 176.322.4 183.723.0 <0.001
LDL cholesterol 96.617.5 97.317.2 98.017.3 98.317.6 97.017.8 0.14
HDL cholesterol 36.34.6 42.04.6 46.14.9 51.25.9 62.310.2 <0.001
Triglycerides 184.384.7 158.267.8 148.166.3 134.855.6 122.054.8 <0.001
Cardiovascular history
Myocardial infarction 1268 (62.4%) 1211 (61.3%) 1028 (56.2%) 1037 (57.0%) 1014 (53.8%) <0.001
Coronary artery bypass graft 1018 (50.1%) 943 (47.7%) 865 (47.3%) 800 (44.0%) 811 (43.0%) <0.001
Coronary angioplasty 1094 (53.8%) 1072 (54.2%) 997 (54.5%) 992 (54.5%) 1019 (54.1%) 0.82
Cerebrovascular accident 121 (6.0%) 105 (5.3%) 82 (4.5%) 96 (5.3%) 83 (4.4%) 0.044
Angina 1665 (81.9%) 1613 (81.6%) 1514 (82.8%) 1455 (80.0%) 1534 (81.4%) 0.36
Peripheral vascular disease 279 (13.7%) 241 (12.2%) 207 (11.3%) 191 (10.5%) 192 (10.2%) <0.001
Hypertension 1132 (55.7%) 1072 (54.2%) 992 (54.3%) 959 (52.7%) 1005 (53.3%) 0.082
Arrhythmia 409 (20.1%) 336 (17.0%) 335 (18.3%) 317 (17.4%) 345 (18.3%) 0.23
Congestive heart failure 197 (9.7%) 162 (8.2%) 122 (6.7%) 117 (6.4%) 122 (6.5%) <0.001
Diabetes mellitus 411 (20.2%) 338 (17.1%) 252 (13.8%) 229 (12.6%) 189 (10.0%) <0.001
Data are expressed as meanSD or n (%). Comparisons of baseline characteristics were based on linear regression for continuous variables and Cochran-Armitage trend test for
categorical variables. HDL indicates high-density lipoprotein; LDL, low-density lipoprotein.
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In population studies, high HDL cholesterol levels correlate
inversely with the risk of having a cardiovascular event.1 HDLs
have several potentially cardioprotective properties, including
participation in reverse cholesterol transport,17 inhibition of
vascular inﬂammation,18 reduction of oxidative stress in
macrophages,19 prevention of oxidation of LDLs,20 promotion
of endothelial function and repair,21,22 and promotion of
angiogenesis.23 As a decline in renal function is a recognized
cardiovascular risk factor,24 it is likely that a higher HDL
cholesterol level may predict a lower risk of renal function
decline in atorvastatin patients with normal eGFR. In fact,
lipotoxicity has been suggested as one of the underlying
mechanisms for the renal disease development.25 Dyslipi-
demia could cause renal lipid accumulation at both the
glomerular and tubular level, and hence alternations in
glomerular ﬁltration barrier and renal failure.25
Besides reduced HDL cholesterol levels, elevated triglyc-
erides are often found in patients with CKD, and are
associated with rapid loss of renal function.25 Although
HDL cholesterol levels often correlate inversely with triglyc-
erides, the association of high HDL cholesterol levels with
lower risk of eGFR decline in statin-treated patients with
normal renal function observed in this study was likely to be
independent of triglycerides, as the data were adjusted for
triglycerides at baseline and month 3. Interestingly, a recent
Mendelian randomization study has suggested a causal
relationship of HDL cholesterol levels, but not LDL choles-
terol and triglyceride levels, with renal function.26 Moreover,
in patients with CKD, genetic variants of apoL-1, a minor
apolipoprotein of HDLs, is associated with CKD progression,
which may explain the racial disparities in CKD progression
risk.27,28 Further studies are needed to establish the role of
HDLs and their apolipoproteins, including apoL-1 in CKD
progression.
Previous longitudinal studies investigating the relationship
of HDL cholesterol or apoA-I levels on kidney function have
not been well established. In a study of 12 728 participants
from the ARIC (Atherosclerosis Risk in Communities) study
with a follow-up period of 2.9 years, lower levels of HDL
cholesterol and HDL2 cholesterol predicted a higher risk of
renal dysfunction, which was deﬁned as a rise in creatinine
levels.3 In another study of 4483 healthy men from the
Physicians’ Health Study, lower baseline HDL cholesterol
levels also predicted a higher risk of elevated creatinine levels
after 14 years.4 In a community-based cohort of 2585 men
and women, long-term, 12-year averaged HDL cholesterol was
found to be a predictor of developing kidney disease after
18.5 years of follow-up.5 However, in a previous study of 73
nondiabetic patients with primary chronic renal disease, HDL
cholesterol levels were not related to the rate of renal
progression over 3 years.6 In a more recent prospective study
of 3939 patients with CKD from the CRIC (Chronic Renal
Insufﬁciency Cohort) study, all serum lipids, including HDL
cholesterol, were not related to the progression of kidney
disease over a median follow-up period of 4.1 years.7 From
these studies, lower HDL cholesterol levels were more likely
to be predictive of renal function decline in healthy people
than in those with existing renal function impairment. This
trend was consistent with our study of statin-treated patients.
However, improvement in renal function was not assessed in
these previous studies. In this study, the association of HDL
cholesterol at month 3 with decline or improvement in eGFR
was not signiﬁcant in the unadjusted model, but a signiﬁcant
association was revealed after adjusting the data for age, sex,
and treatment allocation. This suggests important confound-
ing effects of age and sex, which may also contribute to the
inconsistent ﬁndings on the relationship of HDL cholesterol
and renal function in the literature.
Table 3. Baseline and Follow-Up Changes in eGFR by Quintile of HDL Cholesterol Level at Month 3
HDL Cholesterol at Mo 3
P for Trend
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
(19–38 mg/dL) (39–43 mg/dL) (44–48 mg/dL) (49–55 mg/dL) (56–116 mg/dL)
N 2033 1977 1828 1819 1885
Baseline eGFR
≥60 mL/min per 1.73 m2 1383 (68.0%) 1330 (67.3%) 1208 (66.1%) 1205 (66.3%) 1193 (63.3%) 0.002
30 to 59 mL/min per 1.73 m2 635 (31.2%) 642 (32.5%) 613 (33.5%) 606 (33.3%) 687 (36.4%)
<30 mL/min per 1.73 m2 15 (0.7%) 5 (0.3%) 7 (0.4%) 8 (0.4%) 5 (0.3%)
Mean baseline eGFR, mL/min per 1.73 m2 65.513.1 65.011.9 64.812.2 65.112.3 64.512.4 0.034
Mean change from baseline to
last visit, mL/min per 1.73 m2
3.010.3 3.89.7 3.69.8 3.19.1 2.99.7 0.26
P for change <0.001 <0.001 <0.001 <0.001 <0.001
All data are expressed as meanSD, or n (%). eGFR indicates estimated glomerular ﬁltration rate; HDL, high-density lipoprotein.
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It is not clear why the inverse relationship between HDL
cholesterol levels and renal function was not observed in the
atorvastatin-treated patients with reduced baseline levels of
eGFR. It is possible that the smaller sample size of patients
with reduced eGFR provided insufﬁcient statistical power.
However, it is also possible that the cardioprotective functions
of HDLs are impaired in patients with reduced eGFR, with HDL
cholesterol levels no longer reﬂecting HDL function. Although
the underlying mechanism is unknown, it has been reported
that HDL particles from patients with CKD have impaired
antioxidative and anti-inﬂammatory properties, possibly sec-
ondary to a reduced activity of HDL-associated enzymes, such
as paraoxonase29,30 and also to glycation of apoA-I.31 Further
studies using HDL functional assays may help to elucidate this
hypothesis.
It should be noted that the post hoc analysis reported here
has some limitations. The participants included in this analysis
showed signiﬁcant difference in some baseline characteristics,
such as sex, white race, total cholesterol, LDL cholesterol, and
triglyceride levels compared with participants excluded from
the analysis. Therefore, we could not exclude the possibility of
selection bias. However, such selection bias should be small as
we included 9542 (95.4%) out of the total 10 001 participants
from the TNT trial and data were adjusted for these baseline
characteristics.Moreover, therewas no signiﬁcant difference in
HDL cholesterol levels at baseline and month 3. Another
limitation is that we assessed renal function using eGFR only,
with no data available on the presence or absence of
albuminuria. Furthermore, since the cause of renal function
impairment in the TNT population was unknown, any general-
izations should be made with caution. Nevertheless, despite a
reduced HDL cholesterol level being a frequent ﬁnding in
patients with CKD, this analysis does not suggest any causal
relationship between HDLs and renal function.
In conclusion, higher HDL cholesterol levels were associ-
ated with lower risk of eGFR decline in patients with normal
eGFR and treated with atorvastatin. However, in patients with
lower levels of eGFR, higher levels of HDL cholesterol were
not associated with an improvement in eGFR. Further study is
needed to conﬁrm these ﬁndings.
Table 4. Univariate and Multivariate Analyses of the Association of HDL Cholesterol at Month 3 With Decline and Improvement in
eGFR
Outcomes N Outcome (%)
Unadjusted model Model 1 Model 2
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Decline in eGFR among participants with normal baseline eGFR (≥60 mL/min per 1.73 m2)
HDL cholesterol
Per 10-mg/dL increase 6319 23.1 1.05 (1.00–1.09) 0.056 0.89 (0.85–0.93) <0.001 0.93 (0.87–1.00) 0.047
Quintile
1 1383 21.5 1.00 (referent)  1.00 (referent)  1.00 (referent) 
2 1330 24.0 1.14 (0.98–1.34) 0.094 1.00 (0.85–1.17) 0.95 1.04 (0.88–1.23) 0.67
3 1208 23.0 1.09 (0.92–1.28) 0.33 0.82 (0.69–0.97) 0.018 0.88 (0.73–1.06) 0.19
4 1205 23.4 1.11 (0.94–1.30) 0.23 0.78 (0.66–0.92) 0.004 0.85 (0.69–1.04) 0.12
5 1193 23.9 1.11 (0.95–1.31) 0.19 0.68 (0.57–0.80) <0.001 0.77 (0.61–0.97) 0.028
P for trend 0.32 <0.001 0.006
Improvement in eGFR among participants with abnormal baseline eGFR (<60 mL/min per 1.73 m2)
HDL cholesterol
Per 10 mg/dL increase 3223 52.9 1.00 (0.96–1.04) 0.94 1.10 (1.05–1.14) <0.001 1.07 (1.00–1.14) 0.043
Quintile
1 650 51.5 1.00 (referent)  1.00 (referent)  1.00 (referent) 
2 647 56.6 1.14 (0.98–1.32) 0.082 1.18 (1.02–1.37) 0.029 1.10 (0.94–1.29) 0.23
3 620 50.0 0.95 (0.81–1.11) 0.52 1.09 (0.94–1.28) 0.27 1.00 (0.84–1.20) 0.97
4 614 52.8 1.02 (0.88–1.19) 0.76 1.21 (1.04–1.42) 0.014 1.10 (0.91–1.33) 0.32
5 692 53.5 1.03 (0.88–1.19) 0.73 1.37 (1.17–1.59) <0.001 1.16 (0.93–1.44) 0.18
P for trend 0.73 <0.001 0.27
Model 1: Data were adjusted for age, sex, and treatment allocation at baseline. Model 2: Data were further adjusted for smoking status, body mass index, systolic blood pressure, fasting
glucose, low-density lipoprotein cholesterol, triglyceride levels, ratio of apolipoprotein B to apolipoprotein A-I, and the presence or absence of a history of diabetes mellitus, myocardial
infarction, cerebrovascular accident, and hypertension at baseline, as well as low-density lipoprotein cholesterol and triglycerides at month 3 of the trial. CI indicates conﬁdence interval;
eGFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; HR, hazard ratio.
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